ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: SINGLE CENTRE EXPERIENCE (EBMT 2026) - Feb 7, 2026 - Abstract #P308; Pres time: Mar 22, 2026; 08:30 AM - 06:00 PM; Location: ePoster Area; "All transplants used peripheral blood as stem cells source and received antifungal and antiviral prophylaxis (letermovir for CMV-seropositive since available), as well as graft-versus-host disease (GVHD) prophylaxis with different regimens...Four received radiotherapy and 2 splenectomy.Seven patients received pre-transplant ruxolitinib; two responded to treatment: one had initial response that later lost, and the other one switched to momelotinib because of secondary anemia.Regarding donor type: 40% (6/15) were from matched related donors, 40% (6/15) mismatch unrelated, 13.3% (2/15) matched unrelated and 6.6% (1/15) haploidentical.Most commonly conditioning regimen was fludarabine-busulfan. Four patients received TBF (thiotepa, busulfan and fludarabine) and the rest other regimens (BuCy, FluMel).For GVHD prophylaxis, cyclosporine A was mainly used in combination with other immunosuppressants (methotrexate, mycophenolate mofetil)... Our cohort supports that AHSCT..."
Clinical • Chronic Graft versus Host Disease • Essential Thrombocythemia • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Myelofibrosis • Polycythemia Vera • Transplantation • ASXL1 • CALR • JAK2 • TP53
|
|
Guillermo Morán Cortés1; Laura Contreras Rujas1; Bernardo Manuel Soto Román1; Ángela Figuera Álvarez1; Rafael De La Cámara De Llanza1; Valle Gómez García De Soria1; Adrián Alegre Amor1; Beatriz Aguado Bueno1
|